Dr. Kai Zhang 张凯
Chief Physician
Department of Cancer Prevention, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Tumor screening, early diagnosis and treatment, genetic counseling for cancer, and health management related to tumors and physical examinations.
Professional roles
- Vice Chair, Working Committee of the National Health Commission's Chronic Disease Health Management-Cancer Screening and Early Diagnosis Training Project
- Member, Expert Committee for Lung Cancer and Breast Cancer Screening and Early Diagnosis Guidelines, National Cancer Center
- Deputy Leader, Physical Examination Assessment Group, Health Management Branch, Chinese Medical Association
- Standing Committee Member, Family Hereditary Tumor Branch, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Kai). Papers usually list the name as Kai Zhang or Zhang K.
Selected publications
92 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Life Sci, 2026 (first author): Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression. PubMed 42869130
- Mol Cancer, 2026 (first author): Exploring clinically anchored therapeutic stratification and tumor-stroma heterogeneity using patient-derived 3D bioprinted primary liver cancer models. PubMed 42928279
- Trends Cancer, 2024 (first author): Circulating cell-free DNA-based multi-cancer early detection. PubMed 37709615
- Clin Transl Med, 2022 (first author): FAM135B sustains the reservoir of Tip60-ATM assembly to promote DNA damage response. PubMed 35979619
- BMC Cancer, 2021 (senior author): Characteristics of 1270 Chinese sibling pairs with cancer. PubMed 34525964
- J Transl Med, 2021 (first author): Establishment, validation and evaluation of predictive model for early relapse after R0 resection in hepatocellular carcinoma patients with microvascular invasion. PubMed 34229698
- Int J Gen Med, 2021 (first author): Establishment and Evaluation of a Predictive Model for Early Postoperative Recurrence of Hepatocellular Carcinoma in Patients with Microvascular Invasion. PubMed 34113155
- Ann Palliat Med, 2021 (first author): A practical nomogram from the SEER database to predict the prognosis of hepatocellular carcinoma in patients with lymph node metastasis. PubMed 33752423
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion